Does WellCare Cover Prolia?

How WellCare Plans Classify Prolia Coverage

WellCare covers Prolia primarily through the medical benefit rather than the pharmacy benefit because denosumab is administered by a healthcare provider in an office or clinic setting. This classification matters for your wallet.

Under original Medicare, Part B covers injectable drugs that a patient cannot self-administer. The Centers for Medicare & Medicaid Services (CMS) explicitly lists denosumab as a Part B drug when given by a physician. WellCare Medicare Advantage plans follow this framework. Because WellCare contracts with CMS to deliver Medicare benefits, the plan must cover Part B drugs at minimum at the same level as original Medicare [1]. Your Explanation of Benefits will show Prolia billed under medical claims, not prescription drug claims.

For WellCare Medicaid managed care plans, coverage varies by state. WellCare operates Medicaid plans in states including Florida, Georgia, Kentucky, Illinois, and others. Each state Medicaid program maintains its own preferred drug list. In most of these states, denosumab appears on the formulary but requires prior authorization documenting a diagnosis of osteoporosis and, in some cases, failure of or intolerance to a first-line oral bisphosphonate such as alendronate [2]. The Endocrine Society's 2020 clinical practice guideline recommends denosumab as an alternative first-line therapy for postmenopausal osteoporosis, which strengthens medical necessity arguments when filing appeals.

WellCare Dual Special Needs Plans (D-SNPs), designed for individuals eligible for both Medicare and Medicaid, follow the Medicare Part B pathway for Prolia. The Medicaid side may help cover remaining out-of-pocket costs depending on your state's coordination-of-benefits rules.

Prior Authorization Requirements for Prolia on WellCare

Nearly all WellCare plans require prior authorization before the first Prolia injection. The authorization process confirms medical necessity and prevents coverage denials at the point of service.

Your prescribing physician's office will need to submit documentation that includes a confirmed diagnosis of osteoporosis (T-score of <-2.5 at the hip or lumbar spine on DXA scan, or a history of fragility fracture), along with any relevant lab work such as serum calcium and 25-hydroxyvitamin D levels [3]. The American Association of Clinical Endocrinologists (AACE) 2020 guideline defines high-fracture-risk patients as those with a T-score of <-2.5 plus additional risk factors or a prior vertebral or hip fracture. Citing this guideline in the prior authorization request can speed approval.

Some WellCare plans enforce step therapy. Step therapy means the plan requires documentation that you tried and failed (or cannot tolerate) an oral bisphosphonate like alendronate or risedronate before it will approve Prolia. The AACE guideline, however, supports denosumab as initial therapy in patients at very high fracture risk, defined as those with a recent fracture within the past 12 months, fractures while on approved osteoporosis therapy, multiple fractures, or a T-score of <-3.0 [4]. If your physician documents very-high-risk criteria, the step therapy requirement can often be bypassed with a formulary exception request.

Turnaround time for standard prior authorization is typically 7 to 14 business days. Urgent requests, such as those for patients with recent fractures, may receive a decision within 24 to 72 hours. If denied, you have the right to appeal. WellCare must process Level 1 appeals within 30 days for standard requests under Medicare rules [1].

What Prolia Will Cost You on a WellCare Plan

Out-of-pocket costs for Prolia under WellCare depend on whether the drug falls under Part B medical coverage or, in rare formulary configurations, Part D pharmacy coverage.

Under Part B, standard Medicare coinsurance is 20% of the Medicare-approved amount after you meet the Part B deductible ($257 in 2025). The Medicare-allowed amount for a Prolia injection (HCPCS code J0897) is approximately $1,100 to $1,400 depending on geographic pricing adjustments [5]. That puts the 20% coinsurance at roughly $220 to $280 per injection, or $440 to $560 per year for two doses. Many WellCare Medicare Advantage plans offer lower coinsurance for Part B drugs. Some plans advertise 0% to 15% coinsurance for physician-administered drugs in network, which would reduce per-dose cost to $0 to $210.

Amgen offers the Prolia Patient Assistance Program for eligible patients. The AMGEN Safety Net Foundation provides free Prolia to patients with household incomes at or below 300% of the federal poverty level who lack adequate coverage. A separate copay card program exists for commercially insured patients, though Medicare beneficiaries are not eligible for copay cards due to federal anti-kickback rules. WellCare Medicaid patients may have zero or minimal out-of-pocket costs depending on state Medicaid copay structures. In Florida, for instance, Medicaid recipients pay $0 for preferred drugs and $0 for physician-administered medications.

The wholesale acquisition cost (WAC) for Prolia is approximately $1,824 per 60 mg prefilled syringe as of 2025 [6]. This number represents the manufacturer's list price before discounts. The actual amount billed to WellCare and the amount WellCare pays the provider are both lower than WAC due to negotiated rates and Medicare fee schedules.

Clinical Evidence Supporting Prolia for Osteoporosis

Understanding the evidence behind Prolia helps you and your physician build the strongest possible case for coverage approval, especially if WellCare requests additional clinical justification.

The FREEDOM trial (N=7,868), a key phase 3 study published in the New England Journal of Medicine, demonstrated that denosumab 60 mg every 6 months reduced the risk of new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo over 36 months in postmenopausal women with osteoporosis [7]. The 10-year extension of FREEDOM showed continued fracture risk reduction with sustained treatment, with cumulative vertebral fracture incidence remaining low at 0.90 to 1.86 per 100 participant-years through year 10 [8].

A head-to-head comparison is relevant for step therapy appeals. The DECIDE trial found that denosumab produced significantly greater increases in bone mineral density (BMD) at the total hip (3.5% vs. 2.6%), femoral neck, and lumbar spine compared with alendronate at 12 months in postmenopausal women already receiving alendronate [9]. Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, noted in his review of denosumab data: "Denosumab provides a unique mechanism of action through RANKL inhibition that offers an important option for patients who cannot take or have failed oral bisphosphonate therapy" [10].

The FDA label for Prolia carries a boxed warning about the risk of multiple vertebral fractures after discontinuation. The AACE guideline recommends transitioning patients to a bisphosphonate if denosumab is stopped, to prevent rebound bone loss [4]. This discontinuation risk actually supports long-term coverage authorization, because starting and then stopping Prolia creates measurable clinical harm.

According to the National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation), approximately 10 million Americans have osteoporosis and another 44 million have low bone density, placing them at increased risk for fractures. Hip fractures alone carry a 20% to 30% one-year mortality rate in older adults [11]. The economic argument for coverage is straightforward: preventing a single hip fracture avoids an estimated $30,000 to $50 to 000 in acute care and rehabilitation costs [12].

How to Verify Your Specific WellCare Plan Covers Prolia

Do not assume coverage based on general information. WellCare operates dozens of distinct plan designs across different states, and formulary details change annually during the Medicare open enrollment period.

Call the member services number on the back of your WellCare ID card. Ask specifically: "Is denosumab (Prolia, HCPCS code J0897) covered under my medical benefit, and what is my coinsurance?" Request the answer in writing or ask the representative to note the call with a reference number. You can also log into the WellCare member portal online and search the plan's formulary or medical policy documents for denosumab.

Your physician's billing office should verify benefits before scheduling the injection. The billing team will submit a predetermination or prior authorization request using diagnosis codes for osteoporosis (M80.x for age-related osteoporosis with fracture or M81.0 for age-related osteoporosis without fracture) along with the relevant HCPCS code. A verified authorization number before the appointment prevents surprise bills.

If your plan denies coverage, the denial letter must include the specific reason. Common denial reasons include missing DXA scan documentation, failure to meet step therapy requirements, or incomplete clinical notes. The Medicare Beneficiary Ombudsman can assist with appeals for Medicare Advantage denials. WellCare is required to provide an independent external review if internal appeals are exhausted [1].

WellCare Medicaid Coverage of Prolia by State

WellCare participates in Medicaid managed care in more than a dozen states. Each state sets its own preferred drug list and prior authorization criteria for denosumab.

In Florida, WellCare's Staywell Medicaid plan covers Prolia with prior authorization. The Florida Agency for Health Care Administration requires documentation of a bone density test and a diagnosis of postmenopausal osteoporosis or osteoporosis in men at high fracture risk [13]. Georgia's Medicaid program similarly covers denosumab with prior authorization and step therapy through an oral bisphosphonate. Kentucky Medicaid, where WellCare has significant enrollment, covers Prolia on its preferred drug list with prior authorization documenting DXA-confirmed osteoporosis.

For Medicaid recipients, the out-of-pocket cost is typically $0 to $3 per physician visit, depending on state copay rules. Federal Medicaid law prohibits copays for certain populations, including pregnant women and children, though osteoporosis treatment predominantly involves adults over 50.

The Medicaid and CHIP Payment and Access Commission (MACPAC) reports that Medicaid covers approximately 85 million Americans as of 2025. Managed care organizations like WellCare must cover all drugs in their state's Medicaid formulary and may add additional drugs to their own formulary. If Prolia is not on your WellCare Medicaid plan's formulary, your physician can request a formulary exception based on medical necessity, citing the FREEDOM trial data and AACE guidelines [4][7].

Alternatives If WellCare Denies or Limits Prolia Coverage

If WellCare denies Prolia coverage or imposes restrictions that delay treatment, several alternatives exist within the same therapeutic category.

Zoledronic acid (Reclast) is an intravenous bisphosphonate given once yearly. The HORIZON-PFT trial (N=7,765) showed that zoledronic acid reduced vertebral fracture risk by 70%, hip fracture risk by 41%, and nonvertebral fracture risk by 25% over 3 years [14]. Because zoledronic acid is also physician-administered, it falls under Part B and may have a similar coverage pathway. Its advantage for coverage purposes is lower cost: the Medicare-allowed amount for zoledronic acid is approximately $300 to $500 per infusion versus $1,100 to $1,400 for Prolia.

Oral bisphosphonates remain the most commonly covered first-line option. Generic alendronate 70 mg weekly costs $4 to $15 per month and is covered on virtually every WellCare formulary without prior authorization [2]. Risedronate and ibandronate are also available as generics. The U.S. Preventive Services Task Force (USPSTF) recommends screening for osteoporosis in women 65 and older and in younger postmenopausal women with elevated fracture risk, but does not specify a preferred drug class for treatment.

For patients at very high fracture risk, anabolic agents such as teriparatide (Forteo) and romosozumab (Evenity) offer bone-building rather than antiresorptive effects. The VERO trial demonstrated that teriparatide reduced new vertebral fractures by 56% compared with risedronate over 24 months in women with severe osteoporosis [15]. Romosozumab, studied in the ARCH trial (N=4,093), reduced vertebral fracture risk by 48% compared with alendronate over 24 months [16]. Both are expensive (WAC exceeds $20,000 per year for teriparatide and $25,000 for romosozumab's 12-month course), and WellCare typically requires even more extensive prior authorization documentation for these agents. Dr. Felicia Cosman, professor of medicine at Columbia University, stated in the 2020 National Osteoporosis Foundation Clinician's Guide: "Sequential therapy beginning with an anabolic agent followed by an antiresorptive is the preferred approach for patients at very high fracture risk" [17].

Tips for Reducing Your Out-of-Pocket Prolia Costs on WellCare

Even with coverage, coinsurance for Part B drugs can add up. A few strategies can lower your annual spend on Prolia.

If you have a WellCare Medicare Advantage plan with a Medicare Supplement (Medigap) policy, the Medigap plan may cover the 20% Part B coinsurance. However, most Medicare Advantage enrollees do not carry Medigap. Check whether your WellCare plan has a maximum out-of-pocket (MOOP) limit for Part B drugs. Once you hit the MOOP, the plan covers 100% of allowed costs for the remainder of the calendar year.

State Pharmaceutical Assistance Programs (SPAPs) exist in several states and may help cover Part B coinsurance for qualifying low-income Medicare beneficiaries. The Medicare.gov plan finder allows you to compare WellCare plan options in your area and see estimated annual drug costs, including Part B coinsurance for physician-administered drugs.

For WellCare Medicaid members, the combination of Medicaid and any applicable state assistance programs usually results in $0 out-of-pocket for Prolia. The key barrier is not cost but prior authorization approval. Having your physician submit complete documentation on the first attempt avoids treatment delays that increase fracture risk.